Vanguard Group Inc. Buys 275,802 Shares of Novavax, Inc. $NVAX

Vanguard Group Inc. grew its stake in shares of Novavax, Inc. (NASDAQ:NVAX) by 1.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 15,470,365 shares of the biopharmaceutical company’s stock after acquiring an additional 275,802 shares during the quarter. Vanguard Group Inc. owned about 0.10% of Novavax worth $103,961,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently modified their holdings of NVAX. AQR Capital Management LLC lifted its position in shares of Novavax by 95.2% during the 1st quarter. AQR Capital Management LLC now owns 44,427 shares of the biopharmaceutical company’s stock valued at $285,000 after acquiring an additional 21,663 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Novavax by 2.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 104,562 shares of the biopharmaceutical company’s stock valued at $678,000 after acquiring an additional 2,750 shares during the period. Caxton Associates LLP bought a new stake in shares of Novavax during the 1st quarter valued at $158,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Novavax by 16.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 312,789 shares of the biopharmaceutical company’s stock valued at $2,005,000 after acquiring an additional 44,105 shares during the period. Finally, Strs Ohio bought a new stake in shares of Novavax during the 1st quarter valued at $167,000. 53.04% of the stock is currently owned by institutional investors.

Novavax News Roundup

Here are the key news stories impacting Novavax this week:

• Positive Sentiment: Novavax’s Q1 report came in ahead of expectations, with revenue and earnings beating forecasts, helping fuel the stock’s recent rally. Novavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On Expectations – What’s Changed
• Positive Sentiment: Investor optimism is being supported by Novavax’s turnaround narrative, with a Seeking Alpha piece highlighting the Pfizer deal as a potential catalyst for longer-term recovery. Novavax: Betting On This Vaccine Maker’s Turnaround Story, After Pfizer Deal
• Positive Sentiment: Shares of vaccine and biotech names, including NVAX, have also been lifted by fears tied to hantavirus news, which briefly boosted demand for the sector. Hantavirus cases spark surge in pharma and biotech stocks — here’s why
• Neutral Sentiment: Novavax is also seeing elevated mention volume from traders and Zacks users, reflecting increased market interest rather than a new fundamental catalyst. Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know
• Neutral Sentiment: Coverage notes that short interest data appears distorted or unavailable, so it does not provide a reliable read-through for the stock right now.
• Negative Sentiment: Some commentary cautions that NVAX’s big recent run may be overextended and risky to chase, which could limit upside if momentum cools. Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes

Novavax Stock Up 1.3%

Shares of NVAX stock opened at $9.62 on Wednesday. Novavax, Inc. has a twelve month low of $5.86 and a twelve month high of $11.97. The company has a market cap of $1.58 billion, a P/E ratio of -16.59 and a beta of 2.37. The business has a fifty day simple moving average of $9.02 and a 200 day simple moving average of $8.23.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.19. Novavax had a negative return on equity of 14.82% and a negative net margin of 14.73%.The business had revenue of $118.90 million during the quarter, compared to the consensus estimate of $79.81 million. During the same period in the prior year, the company earned $2.93 EPS. Novavax’s revenue for the quarter was down 79.0% on a year-over-year basis. As a group, equities research analysts anticipate that Novavax, Inc. will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

NVAX has been the subject of several recent analyst reports. Weiss Ratings downgraded Novavax from a “hold (c-)” rating to a “sell (d)” rating in a research report on Thursday, May 7th. Wall Street Zen upgraded Novavax from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. TD Cowen upped their price objective on Novavax from $8.00 to $9.00 and gave the stock a “hold” rating in a research report on Wednesday, May 6th. Jefferies Financial Group restated a “buy” rating on shares of Novavax in a research report on Thursday, March 12th. Finally, BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, January 20th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and four have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $12.13.

About Novavax

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.